Please try another search
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Jeffrey Crawford | - | - | Chairman of Scientific Advisory Board |
David Grdina | - | - | Member of Scientific Advisory Board |
Frank Castellana | - | 2022 | Member of Corporate Advisory Committee |
Ki-Young Sohn | - | - | Chairman & Chief Executive Officer |
John Choi | - | - | Executive Director |
Hye-Kyung Kim | - | - | Vice Chairman |
Jong-Koo Kang | 69 | 2017 | Director |
Alexander Fleming | - | 2022 | Member of Corporate Advisory Committee & CTO |
Sang-Gon Ko | 71 | 2017 | Director |
Sang-Hee Kim | 89 | 2017 | Director |
Jae-Yong Lee | - | - | VP & Executive Director |
Jae-Wha Kim | - | - | Member of Scientific Advisory Board |
Do-Young Lee | - | - | Chief Scientific Officer & Member of the Board of Directors |
Stephen T. Sonis | - | - | Member of Scientific Advisory Board |
Larry W. Kwak | - | - | Member of Scientific Advisory Board |
Cecil Czerkinsky | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review